ESSA Pharma Inc. Amends Agreement with XenoTherapeutics
Provided By PR Newswire
Last update: Sep 24, 2025
Shareholders expected to receive approximately $0.12 per share in cash upon closing of transaction and up to approximately $0.14 per CVR under revised terms
Read more at prnewswire.com0.1934
-0.01 (-3.78%)
37.2
+0.52 (+1.42%)
Find more stocks in the Stock Screener
